Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci139 in advanced or metastatic solid tumors
NCT07230977Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Jul 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of GenSci139 in solid tumor, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Incidence of adverse events, Dose limiting toxicities at 21 days and 4 more. Started Nov 2025; status: recruiting.
02
Drugs
GenSci139
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07230977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230977.